Oxygen therapeutics: Oxygen delivery without blood

Pharmacotherapy

Volumn 26, Issue 10, 2006, Pages 1453-1464

  Stollings, Joanna L ^a,b   Oyen, Lance J ^a  

^a MAYO CLINIC   (United States)

^b Hospital Pharmacy Services   (United States)

Author keywords

Blood; Blood substitutes; HBOCs; Hemoglobin; Hemoglobin based oxygen carriers; Oxygen therapeutics; Perfluorocarbons; PFCs; Red blood cells; Transfusions

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ACID CITRATE DEXTROSE; BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; FLUOROCARBON; FLUOSOL DA; HBOC 301; HEMOGLOBIN; HEMOSPAN; METHEMOGLOBIN REDUCTASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGLOBIN; PERFLUOROOCTYL BROMIDE; POLITEF; POLYMERIZED HEMOGLOBIN;

ABDOMINAL DISCOMFORT; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; AUTOOXIDATION; BACKACHE; BACTEREMIA; BLEEDING; BLOOD COMPATIBILITY; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COST; CREUTZFELDT JAKOB DISEASE; CRITICALLY ILL PATIENT; ERYTHROCYTE CONCENTRATE; ESOPHAGUS MOTILITY; FEVER; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEMODILUTION; HEMORRHAGIC SHOCK; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; HYPOTENSION; HYPOVOLEMIA; IMMUNOGENICITY; INFECTION RISK; JAUNDICE; JEHOVAH'S WITNESS; MALAISE; MORTALITY; MULTIPLE ORGAN FAILURE; OXYGEN AFFINITY; OXYGEN DISSOCIATION CURVE; PATIENT SAFETY; PERIOPERATIVE PERIOD; RETICULOENDOTHELIAL SYSTEM; REVIEW; SEPTIC SHOCK; SHELF LIFE; SICKLE CELL ANEMIA; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRANSFUSION RELATED ACUTE LUNG INJURY; TRAUMATIC BRAIN INJURY; UNITED STATES; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BLOOD SUBSTITUTES; BLOOD TRANSFUSION; ERYTHROCYTES; FLUOROCARBONS; HEMOGLOBINS; HUMANS; OXYGEN; OXYGEN INHALATION THERAPY; OXYHEMOGLOBINS; RISK ASSESSMENT;

EID: 33749499778     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.10.1453     Document Type: Review

References (47)

1. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005;127:295-307.
2. Groeger JS, Guntupalli KK, Strosberg M, et al. Descriptive analysis of critical care units in the United States: patient characteristics and intensive care unit utilization. Crit Care Med 1993;21:279-91.
3. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002;288:2827-35.
4. Shermock KM, Horn E, Lipsett PA, et al. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005;33:497-503.
5. Shander A. Surgery without blood. Crit Care Med 2003;31(suppl):S708-14.
6. Fowler RA, Berenson M. Blood conservation in the intensive care unit. Crit Care Med 2003;31(suppl):S715-20.
7. Winslow RM. Blood substitutes: refocusing an elusive goal. Br J Haematol 2000;111:387-96.
8. Marwick D. More than a trickle of interest in blood substitutes [editorial]. JAMA 1994;271:895.
9. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994;31:355-60.
10. Ho J, Sibbaid WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 2003;31(suppl):S687-97.
11. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med 2003;31(suppl):S651-7.
12. Goodnough LT. Risks of blood transfusion. Crit Care Med 2003;31(suppl):S678-86.
13. Kuehnert MJ, Roth VR, Haley R, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-9.
14. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
15. Shorr AF, Jackson WL, Kelly KM, Fu M, Kollef MH. Transfusion practice and blood stream infections in critically ill patients. Chest 2005;127:1722-8.
16. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;33:721-6.
17. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2001;40:1207-13.
18. Goodfellow LM. Application of pulse oximetry and the oxyhemoglobin dissociation curve in respiratory management. Crit Care Nurs Q 1997;20(2):22-7.
19. Scott MG, Kucik DF, Goodnough LT, Monk TG. Blood substitutes: evolution and future applications. Clin Chem 1997;43:1724-31.
20. Cohn SM. Oxygen therapeutics in trauma and surgery. J Trauma 2003;54:S193-8.
21. Hill SE. Oxygen therapeutics: current concepts. Can J Anesth 2001;48:S32-40.
22. Creteur J, Vincent JL. Hemoglobin solutions. Crit Care Med 2003;31(suppl):S698-707.
23. Stowell CP, Levin J, Speiss BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion 2001;41:287-99.
24. Stowell CP. Hemoglobin-based oxygen carriers. Curr Opin Hematol 2002;9:537-43.
25. Hameed SM, Aird WC, Cohn SM. Oxygen delivery. Crit Care Med 2003;31(suppl):S658-67.
26. Ali AC, Campbell JA. Interference of o-raffinose cross-linked hemoglobin with routine Hitachi 717 assays. Clin Chem 1997;43:1794-6.
27. Cuignet OY, Wood BL, Chandler WL, Spiess, BD. A second-generation blood substitute (perfluorodichlorooctane emulsion) generates spurious elevations in platelet counts from automated hematology analyzers. Anesth Analg 2000;90:517-22.
28. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999;282:1857-64.
29. Greenburg AG, Kim HW. Hemoglobin-based oxygen carriers. Crit Care 2004;8(suppl 2):S61-4.
30. Moore EE. Blood substitutes: the future is now. J Am Coll Surg 2003;196:1-17.
31. Northfield Laboratories Inc. Northfield Laboratories Inc. announces results of fourth interim analysis of PolyHeme pivotal phase III study [press release]. November 15, 2005. Available from http://phx.corporate-ir.net/phoenix. zhtml?c= 91374&p=irol-newsArticle&ID=782811&highlight=. Accessed January 7, 2006.
32. Biopure Corporation. Hemopure: clinical development, 2005. Available from http://www.biopure.com. Accessed January 7, 2006.
33. Biopure Corporation. A safety/efficacy study of Hemopure to enhance tissue preservation during cardiopulmonary bypass surgery. March 9, 2006. Available from http://www. clinicaltrials.gov/ct/show/NCT00301535?order=1. Accessed April 17, 2006.
34. Hemosol Corporation. Hemosol announces second quarter 2003 financial results. August 14, 2003. Available from http://www.hemosol.com/presspop.cfm? newsID=2164. Accessed January 7, 2006.
35. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998;187:113-22.
36. Gould SA, Moore EE, Hoyt DB, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002;195:445-55.
37. Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 2002;124:35-42.
38. Cohn SM. Alternatives to blood in the 21st century. Crit Care 2004;8(suppl 2):S15-17.
39. Cheng DCH. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery. Can J Anesth 2001;48:S41-8.
40. Sangart Inc. Sangart announces positive phase II results for Hemospan oxygen transport agent; presentation of results at 35th critical care congress. November 1, 2005. Available from http://www.sangart.com/press/?pID=1648580908. Accessed January 7, 2006.
41. Sangart Inc. Sangart initiates phase II clinical trial for Hemospan. July 19, 2005. Available from http://www.sangart .com/press/?pID=1045727680. Accessed January 7, 2006.
42. Reid TJ. Hb-based oxygen carriers: are we there yet? Transfusion 2003;43:280-7.
43. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996;82:390-405.
44. King DR, Cohn SM, Proctor KG. Resuscitation with a hemoglobin-based oxygen carrier after traumatic brain injury. J Trauma 2005;59:553-62.
45. Cothren D, Moore EE, Offner PJ, Haenel JB, Johnson JL. Blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness. N Engl J Med 2002;346:1097-8.
46. Cothren CC, Moore EE, Long JS, Haenel JB, Johnson JL, Ciesla DJ. Large volume polymerized haemoglobin solution in a Jehovah's Witness following abruption placentae. Transfus Med 2004;14:241-6.
47. Mullon J, Giacoppe G, Clagett C, et al. Transfusion of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 200;342:1638-43.